Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  SAP SE
2. Date of Event Requiring Statement (Month/Day/Year)
05/17/2016
3. Issuer Name and Ticker or Trading Symbol
CASTLIGHT HEALTH, INC. [CSLT]
(Last)
(First)
(Middle)
DIETMAR-HOPP-ALLEE 16
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
05/27/2016
(Street)

WALLDORF, 2M 69190
6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Class B Common Stock 4,762,658
I (1)
See Footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant   (3)   (4) Class B Common Stock 1,905,063 $ 4.91 I (1) See Footnote (2)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SAP SE
DIETMAR-HOPP-ALLEE 16
WALLDORF, 2M 69190
    X    
SAP America, Inc.
3999 WEST CHESTER PIKE
NEWTOWN SQUARE, PA 19073
    X    
SAP Technologies, Inc.
3999 WEST CHESTER PIKE
NEWTOWN SQUARE, PA 19073
    X    

Signatures

/s/ Michael Kleinemeier, Authorized Signatory, on behalf of SAP SE 06/01/2016
**Signature of Reporting Person Date

/s/ Jochen Scholten, Authorized Signatory, on behalf of SAP SE 06/01/2016
**Signature of Reporting Person Date

/s/ Brad C. Brubaker, Corporate Secretary, on behalf of SAP America, Inc. 06/01/2016
**Signature of Reporting Person Date

/s/ Brian Stine, Assistant Secretary, on behalf of SAP Technologies, Inc. 06/01/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These securities were previously reported as directly owned by SAP SE.
(2) This form is a joint filing by SAP SE, SAP America, Inc. and SAP Technologies, Inc. The reported securities are beneficially owned directly by SAP Technologies, Inc., which is a wholly owned subsidiary of SAP America, Inc., which is a subsidiary of SAP SE. SAP SE and SAP America, Inc. are indirect beneficial owners of the reported securities.
(3) The Warrant becomes exercisable on the date that Castlight Health, Inc. and SAP Technologies, Inc. (or one of its affiliates) enter into (i) an agreement pursuant to which Castlight Health, Inc. will participate in SAP SE's "Connected Health Platform" (the "Platform Agreement") and (ii) an agreement pursuant to which SAP Technologies (or one of its affiliates) will distribute or co-market Castlight Health Inc.'s solutions (the "Distribution Agreement").
(4) The Warrant will expire four years from the date Castlight Health, Inc. and SAP Technologies, Inc. (or one of its affiliates) enter into the Platform Agreement and the Distribution Agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.